Latest Amgen Stories
THOUSAND OAKS, Calif., Feb.
RnRMarketResearch.com adds "Peritoneal Cancer - Pipeline Review, H1 2015" to its store. This provides an overview of the Peritoneal Cancer's therapeutic pipeline. DALLAS, Feb.
Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Feb.
RnRMarketResearch.com adds "Asthma - Pipeline Review, H1 2015" to its store. The report provides an overview of the Asthma's therapeutic pipeline. DALLAS, Feb.
FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder THOUSAND OAKS,
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
THOUSAND OAKS, Calif., Jan. 22, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan.
-- First biosimilar from Samsung Bioepis to advance to EMA regulatory review -- INCHEON, South Korea, Jan.
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.